Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al

We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We emphasize the importance of persistence, as assessed through the Drug Retention Rate (DRR), a validated measure in observational studies of biologic therapies. The DRR reflects a complex interplay of factors, including efficacy, safety, and patient choice, making it a valuable indicator of therapeutic performance. We agree that adherence is an interesting topic, but argue that its absence does not invalidate persistence data. Our study was designed to evaluate treatment persistence, not behavioural pharmacology. We believe that our methodological rigor, real-world design, and consistency with international literature make our data a reliable reference for understanding ixekizumab persistence in routine clinical pratice.

Authors

Institutions

Publication Details

Journal
Journal of Psoriasis and Psoriatic Arthritis
Published
2026-06-08
DOI
https://doi.org/10.1177/24755303261446210
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al

Eleonora Celletti, Daniele Santilli, Pietro Del Biondo, Rosario Foti et al.
Journal of Psoriasis and Psoriatic Arthritis
Spondyloarthritis Studies and Treatments
article

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al

Eleonora Celletti, Daniele Santilli, Pietro Del Biondo, Rosario Foti, P. Del Medico, Antonio Marchetta, Francesca Ometto, Francesca Serale, Viviana Ravagnani, Alessandra Bezzi, Gianluca Santoboni, Eleonora Di Donato, Claudio Angrisani, Maddalena Larosa, Gianluca Smerilli, Giuditta Adorni, Valeria Nucera, Natalia Mansueto, Fabio Mascella, Marta Priora, Dario Camellino, Gianluca Lucchini, Camilla Mazzanti, Cecilia Giampietro, Guido Rovera, Aldo Biagio Colella Molica, Enrico Fusaro, Gerolamo Bianchi, Alberto Lo Gullo, Emanuela Sabatini, Andrea Becciolini, Maria Chiara Ditto, Rosetta Vitetta, Palma Scolieri, Giorgio AMATO, Mirco Magnani, Myriam Di Penta, Davide Murgia, Rosalba Caccavalle, Massimiliano De Simone, Federica Lumetti, Romina Andracco, Bernd Raffeiner, Marino Paroli, Elisa Visalli, Ilaria Platè, Francesco Girelli, Alarico Ariani, Francesco Colella Molica, Alessandro Volpe, Simone Bernardi, Antonella Farina, Vincenzo Bruzzese, Eugenio Arrigoni, Aurora Ianniello, Ylenia Dal Bosco, Elena Bravi, Simone Parisi, Olga Addimanda, Dilia Giuggioli, Roberta Foti, Massimo Reta, Gilda Sandri, Francesco De Lucia, Giulio Ferrero, Veronica Franchina, Carlo Salvarani
article en

Abstract

We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We emphasize the importance of persistence, as assessed through the Drug Retention Rate (DRR), a validated measure in observational studies of biologic therapies. The DRR reflects a complex interplay of factors, including efficacy, safety, and patient choice, making it a valuable indicator of therapeutic performance. We agree that adherence is an interesting topic, but argue that its absence does not invalidate persistence data. Our study was designed to evaluate treatment persistence, not behavioural pharmacology. We believe that our methodological rigor, real-world design, and consistency with international literature make our data a reliable reference for understanding ixekizumab persistence in routine clinical pratice.

Journal of Psoriasis and Psoriatic Arthritis
Polyclinic Medical Center (US), Association for Symbolic Logic (US), Trinity Hospital of Augusta (US), Amoud University (SO), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Santa Chiara (IT), Azienda Unita' Sanitaria Locale Di Modena (IT), Ospedale di Bolzano (IT), L'organizzazione Ospedale di Civitanova M (IT), AULSS 2 Marca Trevigiana (IT), Ospedale Sacro Cuore Don Calabria (IT), Ospedale Garibaldi (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Azienda Ospedaliero-Universitaria di Modena (IT), CTO Andrea Alesini (IT), Ospedale G.B. Morgagni - L.Pierantoni (IT), Azienda Ospedaliera Sant'Andrea (IT), Ospedale di Belcolle (IT), Ospedale Regina Margherita (IT), Guglielmo da Saliceto Hospital (IT), Ospedale SS. Annunziata (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale Santa Corona (IT), Polyclinic General Hospital (GR), University of Milano-Bicocca (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 6%
Spondyloarthritis Studies and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.